REPLIGEN CORP (RGEN) Stock
RGEN has an Alpha Score of 33 out of 100 (poor), computed on Nov 4, 2026 from 3 of 4 sub-scores. 2 members of Congress disclosed 7 trades in RGEN since 2025: 3 purchases and 4 sales, most recently Lisa McClain (sale, Oct 31, 2025). 6 of the hedge funds AlphaScala tracks reported RGEN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Maverick Capital's at $270.77M. Company insiders reported 0 open-market buys and 7 sales on SEC Form 4 in the 90 days to Nov 6, 2026. Its trailing P/E ratio is 229.8 and its net margin -1.5% (key statistics as of Nov 1, 2026).
What is RGEN's Alpha Score?
How it works →Alpha Score of 33 reflects weak overall profile with moderate momentum, poor value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 4, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded REPLIGEN CORP (RGEN)?
Most recent: Lisa McClain (sale, Oct 31, 2025); records start Apr 7, 2025.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Lisa McClain R-MI · House | 2025-10-31 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-07-22 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-17 | partial sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-11 | purchase | $1k – $15k |
| Jefferson Shreve R-IN · House | 2025-04-07 | sale | $15k – $50k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all RGEN political trades →Which hedge funds own RGEN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Maverick Capital Lee Ainslie | 1.98M | $270.77M | +31% |
| Citadel Ken Griffin | 376K | $51.34M | -66% |
| Marshall Wace | 282K | $38.49M | NEW |
| Point72 Steve Cohen | 166K | $22.67M | -71% |
| D.E. Shaw David Shaw | 83K | $11.37M | NEW |
| Duquesne Family Office Stanley Druckenmiller | 77K | $10.56M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are REPLIGEN CORP insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 5, 26 | Loeillot Olivier | Chief Executive Officer | SELL | 1.3K | $238K |
| Oct 5, 26 | Loeillot Olivier | Chief Executive Officer | SELL | 4.2K | $798K |
| Sep 24, 26 | Loeillot Olivier | Chief Executive Officer | SELL | 8.4K | $1.6M |
| Sep 24, 26 | Loeillot Olivier | Chief Executive Officer | SELL | 4.5K | $863K |
| Sep 21, 26 | Loeillot Olivier | Chief Executive Officer | SELL | 5.4K | $977K |
| Sep 4, 26 | Loeillot Olivier | Chief Executive Officer | SELL | 3.0K | $504K |
| Aug 20, 26 | Loeillot Olivier | Chief Executive Officer | SELL | 5.4K | $977K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are RGEN's key statistics?
Key statistics as of Nov 1, 2026
How does RGEN's valuation compare with the Healthcare sector?
| Metric | RGEN | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 229.8 | 28.8 | 111 |
| Net margin | -1.47% | 3.66% | 168 |
| Return on equity | -0.56% | 3.80% | 191 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 8, 2026). P/E excludes loss-making companies.
RGEN price chart
Powered by TradingViewWhat does REPLIGEN CORP do?
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems to support the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Headquartered in Waltham, Massachusetts, it serves biopharmaceutical drug developers, contract development and manufacturing organizations (CDMOs), and other life science companies across North America, Europe, and Asia Pacific. The company offers products in four main categories: filtration and fluid management, its largest segment; chromatography, including OPUS pre-packed columns and high-performance resins like AVIPure HiPer for viral vectors; proteins, such as Protein A ligands and affinity chromatography components; and process analytics, featuring slope spectroscopy systems like SoloVPE and FlowVPE. Repligen's technologies enable purification, cell culture growth, and process monitoring, addressing key needs in biologics production for next-generation modalities like gene therapy.